All stocks / CYTOF
Altamira Therapeutics Ltd. CYTOF
Altamira Therapeutics (CYTOF): no warning signs from our rules in the last 12 months. Each fact links to its SEC filing.
OTCIDBermuda
Market listing
- Full name
- ALTAMIRA THERAPEUTICS LTD
- Market tier
- OTC Pink Current
- Trading status
- Active
- Last trade
- Nov 16
News headlines
Altamira Therapeutics Announces Publication Highlighting Potential of RNA Nanoparticles for Disease-Modifying Treatment of Osteoarthritis
2026-04-13 09:00 · News Release
Altamira Therapeutics Provides Business Update and Reports Full Year 2025 Financial Results
2026-03-31 09:00 · News Release
Altamira Therapeutics Announces Release Date for 2025 Annual Report and Financial Statements
2026-03-24 09:00 · News Release
Altamira Therapeutics Announces Allowance of Japanese Patent Application Covering Bentrio Nasal Spray
2026-02-13 09:00 · News Release
Altamira Therapeutics to Present at mRNA-Based Therapeutics Summit
2026-01-23 09:00 · News Release
Altamira Therapeutics Announces Market Approval of Bentrio Nasal Spray in China
2025-12-19 09:00 · News Release
Altamira Therapeutics Announces Certification of Bentrio Nasal Spray under Medical Device Regulation
Headlines only, with links to the full item. Company press releases are written by the company. 2025-11-20 09:00 · News Release
Signals
No warning signs found in the last 12 months of SEC records. That is not a clean bill of health; it only means none of our rules fired.
Shares outstanding
Source: SEC filingsPrice chart
Chart by TradingView. We do not store or publish prices. Live quote on OTC Markets
Recent filings
| 2026-02-27 | 15-12G | FORM 15-12B |
Common questions about CYTOF
Does CYTOF file reports with the SEC?
Yes. Altamira Therapeutics files with the SEC under company number 0001601936. The most recent filing we hold is a 15-12G dated 2026-02-27.
Source recordHow many CYTOF shares are outstanding?
4,662,080 shares as of 2024-12-31, as reported to the SEC.
Source recordHas CYTOF filed reports late?
We found no late-filing notices (NT 10-K or NT 10-Q) in its last 12 months of SEC filings.